BioSpace News Archive

Simulations Plus, Inc. announced record-setting attendance and virtual content delivery for the 2022 MIDD+ Scientific Conference which was held February 16–17, 2022.

Tenaya Therapeutics, Inc., a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, announced participation in two upcoming investor conferences.

Dermata Therapeutics, Inc., a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, announced that the Company will be participating in the 2022 Maxim Group Virtual Growth Conference, taking place March 28-30, 2022.

Open Book Extracts, a cGMP-certified manufacturer and distributor of the industry’s most innovative and highest quality cannabinoid ingredients and finished products, announced the completion of its first randomized, controlled trial on rare cannabinoids, with the support of Radicle Science, a transformative healthtech B-corp validating health and wellness products for the first time.

Neogen Corporation (NASDAQ: NEOG) announced today the results of the third quarter of its 2022 fiscal year, which ended February 28.

Previously offered as a beta application on iOS, Rootines, a patient engagement platform is now available commercially.

Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m. ET on Thursday, March 31, 2022 to discuss financial results for the year ended December 31, 2021.

Stereotaxis announces that Poland’s National Institute of Cardiology, the leading clinical center of cardiology and cardiac surgery in Warsaw, has established the first robotic electrophysiology program in the country with Stereotaxis’ Genesis Robotic Magnetic Navigation system.

Novan, Inc., announced that data from its pivotal Phase 3 study of berdazimer gel 10.3% for the treatment of molluscum contagiosum was selected for an oral presentation at a late-breaker session at the American Academy of Dermatology’s 2022 Annual Meeting.

Revelation Biosciences Inc. outlines details on the upcoming data analysis for Phase 2b viral challenge study (RVL-VRL01) to evaluate the efficacy of intranasal REVTx-9.